CYP2E1 and tuberculosis: Given the activity of PAHs in inducing CYP2E1, smokers taking INH as part of TB therapy may experience increased synthesis of reactive intermediates resulting from further oxidation of oxidised HZ and AcHZ. This could increase the risk of INH-associated hepatotoxicity. However, most studies do not include cigarette smoking as a possible individual risk factor for drug-induced hepatotoxicity (DIH)